Tyra Biosciences, Inc

This early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for si…

This study tests a new medicine called TYRA-300 in children aged 3 to 10 who have achondroplasia (a common form of dwarfism) and still have open growth plates. The goal is to see if the drug is safe and can help them grow faster. About 92 children will take part across multiple c…

This study tests a new oral drug, dabogratinib, in 230 adults with a rare, low-grade cancer of the upper urinary tract. The goal is to see if the drug can make tumors disappear completely within six months. Participants must have a specific genetic marker (FGFR3) and a visible tu…

This study tests a new drug called TYRA-300 in people with a low-grade, intermediate-risk bladder cancer that has not invaded the muscle. The drug targets tumors with specific changes in the FGFR3 gene. About 90 adults will take the drug to see if it shrinks tumors and delays can…